| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1c89ce4d9ac03f9acd8ddede1162f94d |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/H04L63-123 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D215-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D215-233
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/H04J3-0661
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/H04L63-1458 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D215-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-407
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-16 |
| filingDate |
2006-12-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2010-07-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4520e9f1b3160ba0af64ca5d0dd3812c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5b172f102b499490bb4b747c709d2181
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_407ea487f2dd9522896995a62d55807c |
| publicationDate |
2010-07-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-1963271-B1 |
| titleOfInvention |
Quinolone m1 receptor positive allosteric modulators |
| abstract |
The present invention is directed to quinolone compounds of general formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, pain or sleep disorders, and to novel M1 receptor positive allosteric modulator compounds of formulae (II) to (VIII). The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases in which the M1 receptor is involved. |
| priorityDate |
2005-12-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |